Sinaptica Therapeutics Announces Publication of Positive Results from Phase II Trial Evaluating the…
Phase II sham-controlled randomized trial met its primary endpoint with statistical significance; treatment slowed cognitive decline by 82% over 6 months in the treated population compared to sham with no safety issues Key secondary…